Examplepictures of DNA-Structures


Gene therapy targeting cone photoreceptors

CRTD Seminar

Date:09.11.2018, 15:00 - 16:00
Speaker: Prof. Dominik Fischer, University Eye Hospital, Centre for Ophthalmology, Tübingen, Germany
Location: CRTD, ground floor, auditorium right
Host: Prof. Marius Ader

The Fischer group aims to bring promising new therapies to patients with retinal disorders and conducted the first retinal gene therapy trial in Germany. With a focus on genetic therapies, our mission is to understand disease processes leading to blindness, developing treatment strategies and testing promising new drugs in clinical trials.

5 most recent papers
Changes in retinal sensitivity after gene therapy in choroideremia. Fischer et al., Retina 2018: First report on clinical gene therapy trial on eyes in Germany.

AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye. Reichel et al. Mol Ther 2017: Immune considerations in regard to retinal gene therapy.

Codon-Optimized RPGR Improves Stability and Efficacy of AAV8 Gene Therapy in Two Mouse Models of X-Linked Retinitis Pigmentosa. Fischer et al. Mol Ther 2017: Codon optimisation as a mean to sidestep genetic fragility of RPGR for gene therapy.

High Symmetry of Visual Acuity and Visual Fields in RPGR-Linked Retinitis Pigmentosa. Bellingrath et al., Invest Ophthalmol Vis Sci. 2017: This is our initial cohort for RPGR gene therapy. We define suitable endpoints.

Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. Michalakis et al., Mol Ther. 2010: POC paper for the CNGA3 gene therapy trial.

To the top of this page.